| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Pandel Cream on the Market for Psoriasis and Dermatitis MELVILLE, N.Y., March 21, 1997 -- A new cream is now available for the treatment of psoriasis and atopic dermatitis in American adults. Pandel(R) (hydrocortisone buteprate) cream, 0.1% a nonhalogenated corticosteroid was designed to provide idpotency topical activity with low risk of systemiceffects, according to Savage Laboratories(R). "Pandel Cream, 0.1% effectively relieved the signs and symptoms of psoriasis and improved the overall disease condition significantly better than placebo in a three week, double-blind, randomized study of 169 patients with mild to moderate psoriasis," says Dr. David Kaplan, FACP, FAAD, clinical investigator for Savage Laboratories. "Good to excellent responses were recorded for 41.3% of 84 treated patients compared to 18.1% of 85 patients receiving placebo,” Dr. Kaplan added. “Overall, physicians recorded positive efficacy evaluations in more than half of the drug-treated patients in the study. We In a second, double-blind, randomized, placebo-controlled study study of 168 patients with atopic dermatitis, physicians saw an excellent safety profile and a good-to-excellent efficacy profile in the 106 receiving the cream. 'Pandel Cream, 0.1%' was significantly superior to placebo in reducing the skin lesion severity and in overall disease improvement in 77.3% of patients. Good to excellent responses were seen in 68.8%. The most frequent adverse reactions reported for Pandel Cream, 0.1% have included: burning in 4, stinging in 2, and moderate paresthesia in 1 out of 226 patients. Savage Laboratories of Melville, New York, is a subsidiary of Altana Inc.
|